Gapulsid® (cinitapride) – the unique prokinetic indicated for the treatment of upper functional dyspepsia and gastroesophageal reflux disease
Luděk Hrdlička1
+ Affiliation
To read this article in full, please register for free on this website.
Benefits for subscribers
Benefits for logged users
Literature
1. Baqai MT, Malik MN, Ziauddin F. Efficacy and safety of cinitapride in functional dyspepsia. J Pak Med Assoc 2013; 63(6): 747–751.
2. Moayyedi P, Mason J. Clinical and economic consequences of dyspepsia in the community. Gut 2002; 50(Suppl 4): 410–412. doi: 10.1136/gut.50.suppl_4.iv10.
3. Rome IV diagnostic criteria for disorders of gut-brain interaction (DGBI). 2016 [online]. Dostupné z: https: //theromefoundation.org/rome-iv/rome-iv-criteria/2016.
4. Moayyedi P, Lacy BE, Andrews CN et al. ACG and CAG clinical guideline: management of dyspepsia. Am J Gastroenterol 2017; 112(7): 988–1013. doi: 10.1038/ajg.2017.154.
5. Yamasaki T, Hemond C, Eisa M et al. The changing epidemiology of gastroesophageal reflux disease: are patinets getting younger? J Neurogastroenterol Motil 2018; 24(4): 559–569. doi: 10.5056/jnm18140.
6. Ren LH, Chen WX, Qian LJ et al. Addition of prokinetics to PPI therapy in gastroesophageal reflux disease: a meta-analysis. World J Gastroenterol 2014; 20(9): 2412–2419. doi: 10.3748/wjg.v20.i9.2412.
7. Hemalatha PV, Jerad Suresh A, Niraimathi V. Spectrophotometric methods for the estimation of cinitapride and pantoprazole in bulk and oral dosage form. ACAIJ 2013; 12(1): 120–125.
8. Alarcón-de-la-Lastra Romero C, López A, Martín MJ et al. Cinitapride protects against ethanol-induced gastric mucosal injury in rats: role of 5-hydroxytryptamine, prostaglandins and sulfhydryl compounds. Pharmacology 1997; 54(4): 193–202. doi: 10.1159/000139487.
9. Alarcón de la Lastra C, La Casa C, Martin MJ et al. Effects of cinitapride on gastric ulceration and secretion in rats. Inflamm Res 1998; 47(3): 131–136. doi: 10.1007/s000110050301.
10. Portincasa P, Mearin F, Robert M et al. Efficacy and tolerability of cinitapride in the treatment of functional dyspepsia and delayed gastric emptying. Gastroenterol Hepatol 2009; 32(10): 669–676. doi: 10.1016/j.gastrohep.2009.06.013.
11. Marcelínn-Jiménez G, Contreras L, Esquivel J et al. Development of an UPLC-MS/MS micromethod for quantitation of cinitapride inplasma and its application in a pharmacokinetic interaction trial. Bioanalysis 2017; 9(6): 569–579. doi: 10.4155/bio-2016-0210.
12. Du Y, Su T, Song X et al. Efficacy and safety of cinitapride in the treatment of mild to moderate postprandial distress syndrome-predominant functional dyspepsia. J Clin Gastroenterol 2014; 48(4): 328–335. doi: 10.1097/MCG.000000 0000000033.
13. Santos JG, Filpo F, López JM. Cinitapride’s efficacy and tolerability in gastrointestinal tract disorders. Navara University Medicine Magazine 1991.
14. Qi Q, Wang N, Liu H et al. Prokinetics for the treatment of functional dyspepsia: an updated systematic review and network meta-analysis. BMC Gastroenterol 2023; 23(1): 370. doi: 10.1186/s12876-023-03014-9.
15. Surós A, Adell F, De Novoa V et al. Cinitapride in the treatment of gastroesophageal reflux. Comparative study with metoclopramide and placebo. Rev Med Univ Navarra 1992; 37(1): 18–23.